Free Trial
Your Rate Never Goes Up! Save $100 a Year on MarketBeat All Access
Upgrade Now
Claim MarketBeat All Access Sale Promotion
NASDAQ:SUPN

Supernus Pharmaceuticals Q3 2026 Earnings Date & Estimates

Supernus Pharmaceuticals logo
$41.21 -0.02 (-0.05%)
As of 10/21/2026 04:00 PM Eastern

Supernus Pharmaceuticals is estimated to report Q3 2026 earnings on Thursday, October 29, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Supernus Pharmaceuticals in Q3 2026

Supernus Pharmaceuticals is expected to post earnings of $0.49 per share on revenue of $217.56 million. In the same quarter a year earlier Supernus Pharmaceuticals reported $0.46 per share on revenue of $170.00 million. Supernus Pharmaceuticals last reported on August 3, 2026, posting -$1.01 per share and missing the $0.4225 consensus estimate. Supernus Pharmaceuticals has beaten the consensus EPS estimate in 2 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.49
Expected Revenue
$217.56 million
Prior-Year EPS
$0.46
Prior-Year Revenue
$170.00 million
Expected EPS Growth
+6.5%
Expected Revenue Growth
+28.0%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$1.01 (Missed by -$1.4325)
Last Quarter Revenue
$219.06 million
EPS Beat Rate
2 of last 8 quarters

Prepare for the Q3 2026 Call

Supernus Pharmaceuticals Q3 2026 Earnings FAQ

Supernus Pharmaceuticals (NASDAQ:SUPN) is estimated to report Q3 2026 earnings on Thursday, October 29, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Supernus Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Thursday, October 29, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Supernus Pharmaceuticals to post earnings of $0.49 per share for Q3 2026.

The consensus revenue estimate for Supernus Pharmaceuticals is $217.56 million for Q3 2026.

Supernus Pharmaceuticals Earnings Headlines

Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)
October 21 at 7:45 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/21/3385989/19871/en/supernus-announces-orphan-drug-exclusivity-for-onapgo-apomorphine-hcl.html
Supernus Pharmaceuticals Sets October 29 Call for Third Quarter 2026 Results
October 19 at 5:11 PM  |  quiverquant.comQ
Last call for your free 0DTE report
The 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, protect it. This report normally sells for 29.97, but it's available as a free download for a limited time.tc pixel
October 22 at 1:00 AM  |  Profits Run (Ad)
Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026
October 19 at 8:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/19/3383428/19871/en/supernus-pharmaceuticals-to-announce-third-quarter-2026-financial-results-and-host-conference-call-on-october-29-2026.html
Supernus Pharmaceuticals: The Merger Is Priced Like A Retreat, But Reads Like A Reverse Takeover
October 16, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4954763-supernus-pharmaceuticals-merger-priced-retreat-reads-reverse-takeover?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
Supernus Stockholders Approve Merger with Indivior Pharmaceuticals
October 15, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/supernus-stockholders-approve-merger-with-indivior-pharmaceuticals?utm_source=marketbeat.com&utm_medium=referral
See More Supernus Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Supernus Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Supernus Pharmaceuticals and other key companies, straight to your email.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals (NASDAQ:SUPN) is a specialty pharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company’s activities center on epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on products designed to provide differentiated dosing or delivery characteristics.

Supernus’ marketed products include Trokendi XR (topiramate extended-release) for the prevention of migraine headaches and the treatment of certain seizure disorders, Oxtellar XR (oxcarbazepine extended-release) for partial-onset seizures, and Qelbree (viloxazine extended-release) for ADHD in patients six years of age and older. The company also maintains development programs intended to expand its portfolio of neurological treatments.

Founded in 2005 and headquartered in Rockville, Maryland, Supernus primarily serves the U.S. pharmaceutical market through its commercial operations and partnerships. Jack Khattar, who founded the company, serves as its president and chief executive officer. The company’s products are distributed through the U.S. healthcare system, including prescribing physicians, pharmacies, and specialty providers.

View Supernus Pharmaceuticals Profile
Earnings Tools